Across TCGA pan-cancer cohorts, USP17L2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated USP17L2 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher USP17L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated USP17L2 expression acts as an unfavorable survival marker.

LUAD and SARC are the cancer types where USP17L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	27	view →
SARC	OS	Median	All	0.166	0.747	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: USP17L2 tumor-vs-normal RNA expression · all USP17L2 data types